This New Tech Allows Scientists to Observe The Natural Behavior of Pancreatic Cancer Cells

According to a story from EurekAlert! a cell culture platform developed by scientists associated with Hokkaido University will allow researchers to record and observe the natural behaviors of cancer cells.…

Continue Reading This New Tech Allows Scientists to Observe The Natural Behavior of Pancreatic Cancer Cells
BeiGene and Springworks Therapeutics are Collaborating to Research a Combination Therapy for Advanced Solid Tumours
stevepb / Pixabay

BeiGene and Springworks Therapeutics are Collaborating to Research a Combination Therapy for Advanced Solid Tumours

The companies BeiGene Ltd. and SpringWorks Therapeutics have announced that they will collaborate to research the safety and preliminary efficacy of a combination of two drugs: BeiGene’s investigational drug lifirafenib…

Continue Reading BeiGene and Springworks Therapeutics are Collaborating to Research a Combination Therapy for Advanced Solid Tumours

A Study of an Investigational Acute Myeloid Leukaemia and Myelodysplastic Syndrome Drug Has Completed Enrolment

  The company Imago Biosciences, which focuses on developing anti-cancer therapies, is carrying out a Phase 1/2a clinical study of an investigational drug called IMG-7289 as a potential treatment for…

Continue Reading A Study of an Investigational Acute Myeloid Leukaemia and Myelodysplastic Syndrome Drug Has Completed Enrolment

Researchers at UNC Are Experimenting With a New Way to Deliver Drugs For Medulloblastoma

A team of researchers from the University of North Carolina have been exploring an experimental method of delivering drugs to medulloblastoma that involves converting skin cells into stem cells that…

Continue Reading Researchers at UNC Are Experimenting With a New Way to Deliver Drugs For Medulloblastoma
An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation
stevepb / Pixabay

An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation

The US FDA has awarded Breakthrough Therapy Designation to encorafenib (braftoviTM) combined with binimetinib (mektovi®) and cetuximab for use as an investigational (not FDA-approved) treatment of BRAFV600E–mutant metastatic colorectal cancer.…

Continue Reading An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation

The FDA Have Granted Priority Review to Elzonris for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

  A Biologics License Application for ElzonrisTM (also known as tagraxofusp and SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm has been accepted for filing by the United States FDA.…

Continue Reading The FDA Have Granted Priority Review to Elzonris for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm